Natallia Salei

• Led the development, optimization, and validation of in vitro and in vivo assays to evaluate the safety and efficacy of target-specific TCR-T cells, • Conducted comprehensive assessments of TCR T cell safety and therapeutic potential, • Supported identification of lead TCR-T clinical candidates, • Successfully established a mini-scale production of clinically relevant TCR-T cells in the preclinical department, • Prepared regulatory documentation for nonclinical sections (Investigator's Brochure) of Clinic

• Led a research project focused on uncovering molecular pathways that govern tumor cell recognition and elimination by the host immune system, using in vivo models of acute myeloid leukemia (AML), • Designed and executed a genome-wide CRISPR/Cas9 library screen to identify novel therapeutic targets in leukemic cells, • Investigated the impact of different nutritional formulas on tumor progression in AML mouse models (Janakiraman, Salei et al. 2022 Cancer Immunol Immunother.).

• Led a study investigating the developmental dynamics and heterogeneity of kidney-resident dendritic cells and macrophages using mouse genetics (knockout models, fate-mapping reporters) and models of sterile inflammation (Salei et al., 2020, JASN), • Co-developed and characterized a novel mouse model enabling selective depletion of CD64⁺ mononuclear phagocytes in the kidney (Salei et al., 2021, PNAS), • Contributed to the development of a flow cytometry method for profiling muscle-resident immune cells in

• Investigated neutrophil-mediated phagocytosis of apoptotic cells and its role in Leishmania infection using human in vitro models. Demonstrated a novel immune evasion strategy by Leishmania major, which exploits neutrophil apoptotic cell clearance to support its intracellular survival (Salei et al., 2017, PLoS One), • Explored how inflammatory signals regulate the metabolism of innate immune cells, particularly neutrophils, in both human and mouse in vitro models. This work was part of a collaborative pro